Breast cancer in China
This is not a diagnosis. It only helps you find relevant information.
What China offers
China approved trastuzumab rezetecan, a Hengrui HER2 antibody-drug conjugate, in March 2026 for HER2-positive advanced breast cancer after prior anti-HER2 therapy; it is not FDA-approved. Surgery, chemotherapy and radiotherapy are standard at tertiary cancer hospitals, with access through oncology departments or trials.
658 clinical trials are recruiting at sites in China (ClinicalTrials.gov, 2026-10-26). See the trials
Read more about breast cancerHospitals for this
BeijingPeking Union Medical College Hospital (PUMCH), International Medical Services北京协和医院 国际医疗部International deptVerified
BeijingBeijing United Family Hospital北京和睦家医院International deptJCIVerified
GuangzhouSun Yat-sen University Cancer Center中山大学肿瘤防治中心International deptVerified
ShanghaiFudan University Shanghai Cancer Center复旦大学附属肿瘤医院International deptReported
Hainan / Boao LechengRuijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）International deptReported
HangzhouZhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)浙江省肿瘤医院（中国科学院大学附属肿瘤医院）No public intl deptVerified
Patients like you
Your next steps
- Get your records and scans translated into Chinese.
- Contact the international department of one or two hospitals above.
- Check your visa. Many travelers qualify for visa-free entry or transit.
- Plan follow-up care with your doctor at home before you go.